[Clinical Characteristics and Prognosis of B-cell Acute Lymphoblastic Leukemia Patients with IKZF1 Deletion].

OBJECTIVE

To analyze clinical characteristics and prognosis of B-cell acute lymphoblastic leukemia (B-ALL) patients with IKZF1 deletion.

METHODS

72 patients with B-ALL admitted to our hospital from April 2020 to January 2023 were selected, IKZF1 deletion were detected, and clinical characteristics and prognosis were analyzed.

RESULTS

Among the 72 patients, a total of 32 patients (44.4%) were identified with IKZF1 deletions (IKZF1 + ). There was no statistically significant difference in basic clinical data between patients with normal IKZF1 (IKZF1 -) and those with IKZF1 + (P >0.05). The proportion of patients with IKZF1 + in Ph+ group was significantly higher than that in Ph- group (P < 0.05). The main types of IKZF1 + were exon 1-8 deletion (34.4%) and exon 4-7 deletion (31.2%). The median OS and PFS of IKZF1 - patients were significantly longer than those of IKZF1 + patients (OS: 26.0 months vs 16.0 months, χ 2=23.094, P < 0.05; PFS: 26.0 months vs 16.0 months, χ 2=11.150, P < 0.05). Among IKZF1 + patients, the median OS of patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) was significantly longer than that of patients who did not receive allo-HSCT (no reached vs 15.0 months, χ 2=5.685, P < 0.05).

CONCLUSION

IKZF1 deletion is a risk factor affecting the prognosis of B-ALL patients.